Impaired Dihydrotestosterone Catabolism in Human Prostate Cancer: Critical Role of AKR1C2 as a Pre-Receptor Regulator of Androgen Receptor Signaling
Authors:
Open Access
- 1 February 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (3) , 1361-1369
Abstract
We previously reported the selective loss of AKR1C2 and AKR1C1 in prostate cancers compared with their expression in paired benign tissues. We now report that dihydrotestosterone (DHT) levels are significantly greater in prostate cancer tumors compared with their paired benign tissues. Decreased catabolism seems to account for the increased DHT levels as expression of AKR1C2 and SRD5A2 was reduced in these tumors compared with their paired benign tissues. After 4 h of incubation with benign tissue samples, 3H-DHT was predominately catabolized to the 5α-androstane-3α,17β-diol metabolite. Reduced capacity to metabolize DHT was observed in tumor samples from four of five freshly isolated pairs of tissue samples, which paralleled loss of AKR1C2 and AKR1C1 expression. LAPC-4 cells transiently transfected with AKR1C1 and AKR1C2, but not AKR1C3, were able to significantly inhibit a dose-dependent, DHT-stimulated proliferation, which was associated with a significant reduction in the concentration of DHT remaining in the media. R1881-stimulated proliferation was equivalent in all transfected cells, showing that metabolism of DHT was responsible for the inhibition of proliferation. PC-3 cells overexpressing AKR1C2 and, to a lesser extent, AKR1C1 were able to significantly inhibit DHT-dependent androgen receptor reporter activity, which was abrogated by increasing DHT levels. We speculate that selective loss of AKR1C2 in prostate cancer promotes clonal expansion of tumor cells by enhancement of androgen-dependent cellular proliferation by reducing DHT metabolism. [Cancer Res 2007;67(3):1361–9]Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCRMolecular and Cellular Endocrinology, 2005
- The Influence of Androgen Deprivation Therapy on Dihydrotestosterone Levels in the Prostatic Tissue of Patients with Prostate CancerClinical Cancer Research, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Decreased gene expression of steroid 5 alpha‐reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinomaThe Prostate, 2003
- Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolismThe Prostate, 2003
- Immunocytochemical Localization of Type 5 17 β-Hydroxysteroid Dehydrogenase in Human Reproductive TissuesJournal of Histochemistry & Cytochemistry, 1999
- Androgens and prostate cancer: Biology, pathology and hormonal therapyEuropean Journal of Cancer, 1997
- Substrate Specificity, Gene Structure, and Tissue-specific Distribution of Multiple Human 3α-Hydroxysteroid DehydrogenasesJournal of Biological Chemistry, 1995
- Identification and purification of a 36 kDa bile acid binder in human hepatic cytosolFEBS Letters, 1984
- A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostateJournal of Steroid Biochemistry, 1979